Trenda to See Limited Use for CLL, At Least Initially

[Guest guest]

Cephalon's Treanda to see limited uptake for chronic lymphocytic

leukemia, if approved, physicians say

by Klara Czobor and Ha in New York

Published: March 14 2008 17:13 | Last updated: March 14 2008 17:13

This article is provided to FT.com readers by Pharmawire—a news

service focused on providing insight into the most price sensitive

issues in the global pharmaceutical market. www.pharmawire.com

--------------------------------------------------------------------------------\

------------------------

Cephalon's Treanda (bendamustine) will initially see limited uptake in

the first-line setting for chronic lymphocytic leukemia (CLL), if

approved, physicians interviewed by Pharmawire said.

In a number of interviews, the physicians said that more data is

needed to demonstrate superiority over currently used first-line

treatments for the drug to garner widespread use.

Treanda is a novel chemotherapeutic agent, currently under FDA

priority review with a PDUFA date of 20 March to treat CLL.

Hainsworth, who has personal experience using Treanda, is going to be

conducting a trial in patients with lymphoma. He said Treanda is a

relatively well tolerated drug in the lymphoma setting.

The company also expects an October decision on a new drug application

(NDA) for Treanda in relapsed indolent non-Hodgkin's lymphoma.

Cephalon has a current market cap of USD 4.14bn.

Read the full press release at:

www.ft.com/cms/s/2/262988c8-f1e4-11dc-9b45-0000779fd2ac.html